Annual report pursuant to Section 13 and 15(d)

Note 18 - Segments (Tables)

v3.19.1
Note 18 - Segments (Tables)
12 Months Ended
Dec. 31, 2018
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Year Ended December 31, 2018
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Royalty revenue
  $
15,347
    $
    $
    $
15,347
 
License revenue
   
307,174
     
     
     
307,174
 
Grant and other revenue
   
494,997
     
351,833
     
     
846,830
 
Total revenue
   
817,518
     
351,833
     
     
1,169,351
 
Cost of revenue
   
96,636
     
     
     
96,636
 
Research and development expenses
   
3,064,115
     
1,157,766
     
     
4,221,881
 
Selling, general and administrative expenses, excluding depreciation and amortization
(a)
   
     
78,606
     
7,469,144
     
7,547,750
 
Depreciation and amortization
(b)
   
     
     
150,385
     
150,385
 
Loss from operations
(c)
   
(2,343,233
)
   
(884,539
)
   
(7,619,529
)
   
(10,847,301
)
Other expense
(d)
   
     
     
(5,321,270
)
   
(5,321,270
)
Benefit from income taxes
   
1,413
     
534
     
7,806
     
9,753
 
Loss from continuing operations
   
(2,341,820
)
   
(884,005
)
   
(12,932,993
)
   
(16,158,818
)
Income from discontinued operations, net of tax effect
   
1,449
     
     
     
1,449
 
Gain on sale of discontinued operations, net of tax effect
   
43,053
     
     
     
43,053
 
Net loss
   
(2,297,318
)
   
(884,005
)
   
(12,932,993
)
   
(16,114,316
)
Total assets, net of depreciation and amortization:
                               
United States
  $
91,425
     
24,763
     
6,878,129
     
6,994,317
 
International
   
14,330
     
 
     
381
     
14,711
 
Capital expenditures
   
     
     
46,192
     
46,192
 
Year Ended December 31, 2017
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Royalty revenue
  $
9,126
    $
    $
    $
9,126
 
License revenue
   
100,000
     
     
     
100,000
 
Grant and other revenue
   
1,506,232
     
195,079
     
     
1,701,311
 
Total revenue
   
1,615,358
     
195,079
     
     
1,810,437
 
Cost of revenue
   
3,651
     
     
     
3,651
 
Research and development expenses, excluding depreciation and amortization
   
3,784,255
     
729,587
     
     
4,513,842
 
Selling, general and administrative expenses, excluding depreciation and amortization
(a)
   
     
34,484
     
10,895,301
     
10,929,785
 
Depreciation and amortization
(b)
   
     
     
240,166
     
240,166
 
Loss from operations
(c)
   
(2,172,548
)
   
(568,992
)
   
(11,135,467
)
   
(13,877,007
)
Other income (expense)
(d)
   
     
     
(3,912,679
)
   
(3,912,679
)
Benefit from income taxes
   
496,127
     
129,936
     
3,436,426
     
4,062,489
 
Loss from continuing operations
   
(1,676,421
)
   
(439,056
)
   
(11,611,720
)
   
(13,727,197
)
Income from discontinued operations, net of tax effect
   
88,673,053
     
     
     
88,673,053
 
Net income (loss)
   
86,996,632
     
(439,056
)
   
(11,611,720
)
   
74,945,856
 
Total assets, net of depreciation and amortization:
                               
United States
  $
13,065,871
    $
49,001
    $
7,634,237
    $
20,749,109
 
International
   
30,476
     
     
1,851
     
32,327
 
Capital expenditures
   
     
     
33,690
     
33,690